Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $210,051.64 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton sold 15,746 shares of the business’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $13.34, for a total transaction of $210,051.64. Following the transaction, the chief executive officer now owns 911,212 shares in the company, valued at $12,155,568.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jon Congleton also recently made the following trade(s):

• On Friday, June 14th, Jon Congleton sold 16,229 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $12.52, for a total transaction of $203,187.08.
• On Wednesday, June 12th, Jon Congleton sold 16,607 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $12.77, for a total transaction of $212,071.39.

Mineralys Therapeutics Stock Up 6.7 %

Shares of Mineralys Therapeutics stock traded up $0.91 during trading on Friday, reaching $14.48. The company’s stock had a trading volume of 316,110 shares, compared to its average volume of 176,227. The business’s 50-day moving average price is $12.71 and its 200-day moving average price is $12.30. Mineralys Therapeutics, Inc. has a 52 week low of $5.85 and a 52 week high of $16.91. The firm has a market cap of $718.93 million, a PE ratio of -6.58 and a beta of 1.97.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.02). Equities analysts predict that Mineralys Therapeutics, Inc. will post -2.94 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HC Wainwright assumed coverage on shares of Mineralys Therapeutics in a research report on Wednesday. They set a “buy” rating and a $30.00 price objective for the company. Lifesci Capital reaffirmed an “outperform” rating on shares of Mineralys Therapeutics in a research report on Tuesday, March 26th. Finally, The Goldman Sachs Group assumed coverage on shares of Mineralys Therapeutics in a research report on Tuesday, April 2nd. They set a “buy” rating and a $30.00 price objective for the company.

Hedge Funds Weigh In On Mineralys Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Catalys Pacific LLC acquired a new position in shares of Mineralys Therapeutics in the fourth quarter valued at about $79,073,000. Franklin Resources Inc. grew its stake in shares of Mineralys Therapeutics by 55.4% in the fourth quarter. Franklin Resources Inc. now owns 699,467 shares of the company’s stock valued at $6,015,000 after acquiring an additional 249,450 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Mineralys Therapeutics in the fourth quarter valued at about $41,000. CWM LLC grew its stake in shares of Mineralys Therapeutics by 120.0% in the fourth quarter. CWM LLC now owns 5,891 shares of the company’s stock valued at $51,000 after acquiring an additional 3,213 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in shares of Mineralys Therapeutics in the fourth quarter valued at about $191,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.